Alpha 2.0
Login Register
» Authors » Ann Sturdy

Ann Sturdy

Explore the profile of Ann Sturdy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 497
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Hematology
Top 10 Co-Authors
Tommy Rampling
Emma C Thomson
Rostam Osanlou
Nick Andrews
Adrian Palfreeman
Vincenzo Libri
Angela M Minassian
Shirley Todd
Ray Sheridan
Alastair C McGregor
Published In
J Infect
J Antimicrob Chemother
Lancet
Lancet Infect Dis
Thorax
Affiliations
Soon will be listed here.
Recent Articles
1.
Centralising human resources paperwork would improve rotational training
Sturdy A
BMJ . 2024 Mar; 384:q746. PMID: 38531594
No abstract available.
2.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect . 2023 Apr; 86(5):540-541. PMID: 37055303
No abstract available.
3.
Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study
Fink D, Callaby H, Luintel A, Beynon W, Bond H, Lim E, et al.
Lancet Infect Dis . 2022 Dec; 23(5):589-597. PMID: 36566771
Background: The scale of the 2022 global mpox (formerly known as monkeypox) outbreak has been unprecedented. In less than 6 months, non-endemic countries have reported more than 67 000 cases...
4.
Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T-cell leukaemia virus type-1 and type-2 infection in a London teaching hospital with a large solid organ transplant centre
Lee N, Murphy J, Al-Khudairi R, Sturdy A, Mahungu T, Haque T, et al.
Transfus Med . 2022 Apr; 32(3):256-260. PMID: 35474619
Aim: In the United Kingdom, organ donors/recipients are screened for evidence of human T-cell leukaemia virus type-1 and type-2 (HTLV-1/2) infections. Since the United Kingdom is a low prevalence country...
5.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect . 2022 Apr; 84(6):795-813. PMID: 35405168
Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a...
6.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D, et al.
Lancet . 2021 Dec; 398(10318):2258-2276. PMID: 34863358
Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we...
7.
Case of eosinophilic fasciitis during military training in a Nepalese British infantry soldier
Sturdy A, Stratton R, Perez-Machado M, Lamb L
BMJ Mil Health . 2020 Mar; 166(4):277-278. PMID: 32139410
We present the case of a Nepalese British soldier with peripheral oedema and a significantly raised eosinophil count. After extensive investigation looking for a parasitic cause of his illness, he...
8.
A case of progressive breathlessness post partum
Tyebally S, Ghorani E, Kaur B, Sturdy A, Khokhar A, Fisher R, et al.
Thorax . 2016 Jul; 71(9):871-2. PMID: 27369355
No abstract available.
9.
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice
Sturdy A, Goodman A, Jose R, Loyse A, ODonoghue M, Kon O, et al.
J Antimicrob Chemother . 2011 Jun; 66(8):1815-20. PMID: 21642291
Background: Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge to health services globally. Although new drugs are in development, current guidelines still recommend prolonged use of injectable antimicrobials (usually amikacin, kanamycin...